Business Finland Supports Omgenis’s Early Development through Sprint Funding

Business Finland has awarded Sprint funding to support the early development of Omgenis and its innovative treatment technology for periodontitis and peri-implantitis.

The project will enable Omgenis to further assess the technology’s technical and commercial potential, engage with clinical and industry experts, and refine its product-development, regulatory and market-entry plans. The funding represents an important step in Omgenis’s development as an internationally oriented health technology company. During the Sprint project, the company will build the evidence and commercial foundations required for the next phase of product development and future international growth. Business Finland’s support also reflects the project’s potential to address a significant unmet need in the global oral healthcare market.

‍